ORKA Stock Analysis: Oruka Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 6.287m USD | 12M Return: 461.2% | US6876041087 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 79.4M
Warnings
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Oruka Therapeutics (NASDAQ: ORKA) is a clinical-stage biopharmaceutical company headquartered in Menlo Park, California, developing monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead candidates are ORKA-001, an antibody targeting the p19 subunit of IL-23 currently in a Phase 2a PsO trial, and ORKA-002, which targets IL-17A and IL-17F and is in Phase 2 development for PsO, psoriatic arthritis, and related conditions.
The pipeline also includes ORKA-003, directed at an undisclosed pathway, and ORKA-021, a sequential combination regimen pairing ORKA-002 with ORKA-001. As a clinical-stage biotechnology company, Oruka has not yet commercialized a product, meaning its valuation is tied primarily to pipeline progress and the potential for future regulatory approvals in the competitive immunology biologics market.
- ORKA-001 Phase 2a psoriasis data readout approaches
- Competition intensifies from Skyrizi and Taltz in IL-23 market
- Cash runway supports pipeline through key clinical milestones
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.09 > 0.02 and ΔFCF/TA 18.52 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.09 > 3% & CFO -100.9m > Net Income -132.9m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 38.51 > 1.5 & < 3 |
| Outstanding Shares: last quarter (62.9m) vs 12m ago 48.87% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.76 (Total Current Assets 884.6m - Total Current Liabilities 23.0m) / Total Assets 1.14b |
| B: -0.23 (Retained Earnings -262.2m / Total Assets 1.14b) |
| C: -0.19 (EBIT TTM -141.8m / Avg Total Assets 748.4m) |
| D: 44.86 (Book Value of Equity 1.11b / Total Liabilities 24.8m) |
| Altman-Z'' = 50.04 = AAA |
As of September 27, 2026, the stock is trading at USD 84.46 with a total of 499,689 shares traded. Over the past week, the price has changed by -11.06%, over one month by -17.05%, over three months by -2.50% and over the past year by +461.20%.
Current recommended Stop Loss: 77.80 (which is 7.9% or 1.2 ATR below the current price).
Oruka Therapeutics has received a consensus analysts rating of 4.88. Therefore, it is recommended to buy ORKA.
- StrongBuy: 7
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 155 | 83.5% |
P/B = 5.8221
Revenue TTM = 0.0 USD
EBIT TTM = -141.8m USD
EBITDA TTM = -141.7m USD
Long Term Debt = 1.88m USD (estimated: total debt 2.55m - short term 669k)
Short Term Debt = 669k USD (from shortTermDebt, last quarter)
Debt = 2.55m USD (from shortLongTermDebtTotal, last quarter) (leases 2.55m already included)
Net Debt = -871.0m USD (calculated: Debt 2.55m - CCE 873.6m)
Enterprise Value = 5.42b USD (6.29b + Debt 2.55m - CCE 873.6m)
Interest Coverage Ratio = unknown (Ebit TTM -141.8m / Interest Expense TTM 0.0)
EV/FCF = -53.54x (Enterprise Value 5.42b / FCF TTM -101.2m)
FCF Yield = -1.87% (FCF TTM -101.2m / Enterprise Value 5.42b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 83.0k) / Revenue TTM)
Tobins Q-Ratio = 4.75 (Enterprise Value 5.42b / Total Assets 1.14b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 2.55m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -112.0m (EBIT -141.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 38.51 (Total Current Assets 884.6m / Total Current Liabilities 23.0m)
Debt / Equity = 0.00 (Debt 2.55m / totalStockholderEquity, last quarter 1.11b)
Debt / EBITDA = 6.15 (negative EBITDA) (Net Debt -871.0m / EBITDA -141.7m)
Debt / FCF = 8.61 (negative FCF - burning cash) (Net Debt -871.0m / FCF TTM -101.2m)
Total Stockholder Equity = 640.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -17.76% (Net Income -132.9m / Total Assets 1.14b)
RoE = -20.76% (Net Income TTM -132.9m / Total Stockholder Equity 640.0m)
RoCE = -22.09% (EBIT -141.8m / Capital Employed (Equity 640.0m + L.T.Debt 1.88m))
RoIC = -10.03% (negative operating profit) (NOPAT -112.0m / Invested Capital 1.12b)
WACC = 8.49% (E(6.29b)/V(6.29b) * Re(8.49%) + D(2.55m)/V(6.29b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 8.49% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.79 | Cagr: 91.93%
[DCF] Fair Price = unknown (Cash Flow -101.2m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.13 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.62 | Chg30d=-22.02% | Revisions=-55% | Analysts=9
EPS current Year (2026-12-31): EPS=-2.37 | Chg30d=-16.06% | Revisions=-58% | GrowthEPS=-27.9% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-2.86 | Chg30d=-14.85% | Revisions=-25% | GrowthEPS=-20.9% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -55% (up=5, down=21)